Vincent Groppi

Chief Executive Officer at Oricula Therapeutics LLC

Health Technology

Profile

Vincent Groppi is currently the Chief Executive Officer at Oricula Therapeutics LLC.
Prior to this, he worked as the Vice President at Essen BioScience, Inc. from 2007 to 2013.

Vincent Groppi active positions

Companies	Position	Start
Oricula Therapeutics LLC Oricula Therapeutics LLC BiotechnologyHealth Technology Oricula Therapeutics LLC develops medication to prevent hearing loss. Its products is ORC-13661, a medicine to preserve hearing during aminoglycoside therapy, has completed preclinical development and has been approved to move into early human testing for safety, tolerability and pharmacokinetics. The company was founded in 2013 and is headquartered in Seattle, WA.	Chief Executive Officer	-

All active positions of Vincent Groppi

Former positions of Vincent Groppi

Companies	Position	End
Essen BioScience, Inc. Essen BioScience, Inc. Medical SpecialtiesHealth Technology Essen Bioscience, Inc. specializes in developing and manufacturing instruments, software, reagents and consumables for real-time live-cell imaging and data analysis. Its cell imaging and electrophysiology products are used in academic and industrial laboratories. The company was founded by Kirk Schroeder and Brad Neagle in 1999 and is headquartered in Ann Arbor, MI.	Corporate Officer/Principal	-

See the detail of Vincent Groppi's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Vincent Groppi's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Essen BioScience, Inc. Essen BioScience, Inc. Medical SpecialtiesHealth Technology Essen Bioscience, Inc. specializes in developing and manufacturing instruments, software, reagents and consumables for real-time live-cell imaging and data analysis. Its cell imaging and electrophysiology products are used in academic and industrial laboratories. The company was founded by Kirk Schroeder and Brad Neagle in 1999 and is headquartered in Ann Arbor, MI.	Health Technology
Oricula Therapeutics LLC Oricula Therapeutics LLC BiotechnologyHealth Technology Oricula Therapeutics LLC develops medication to prevent hearing loss. Its products is ORC-13661, a medicine to preserve hearing during aminoglycoside therapy, has completed preclinical development and has been approved to move into early human testing for safety, tolerability and pharmacokinetics. The company was founded in 2013 and is headquartered in Seattle, WA.	Health Technology